AIS Healthcare and Grifols Joint Study on Immunoglobulin Treatments
A division of AIS Healthcare, Advanced Infusion Care (AIC), is partnering with Grifols to conduct a joint study on the effects of subcutaneous immunoglobulin (SCIG) products on individuals living with primary immune deficiencies (PID).
The study will observe 60 patients over a three-month period to determine any differences in patient experience and satisfaction with immunoglobulin treatments. The aim is to provide physicians, pharmacists, and nurses with insights to ensure patients receive the best possible therapy for their medical and lifestyle needs.
PID affects approximately 500,000 individuals in the United States, and SCIG treatment is considered effective in preventing infections for these patients. The study is expected to provide additional insights into how to better serve individuals living with primary immune deficiencies through SCIG treatment.
A recent case study by the National Home Infusion Association’s (NHIA) Infusion Journal examined AIC’s model for assessing each patient’s unique circumstances to guide decisions for immunoglobulin treatment. The study highlighted the importance of considering patient preference when choosing the optimal immune globulin (IG) therapy approach.
PID and chronic variable immunodeficiency (CVID) are rare genetic disorders that impair the immune system, requiring lifelong therapy to help patients fight infections and stay healthy. AIC, which operates a network of 200 nurses in 40 states, is committed to advancing quality care and is expanding its research to improve physician understanding around different SCIG products.
Joining forces with Grifols, a global healthcare company, AIC is focused on delivering patient-specific, in-home infusion services, including SCIG treatment. The joint study is expected to contribute insights that will benefit all patients living with PID.
The SOPID study aims to build on the work from the NHIA’s featured case study and provide physicians with more information as they make decisions and plan long-term treatment strategies for individuals with primary immune deficiencies.
As a national leader in providing targeted drug delivery and infusion care, AIS Healthcare has a long history in providing infusion care to people living with immune deficiencies. AIC’s PID patients receive a high level of care, including access to clinical and support staff 24/7.
The SOPID study aims to leverage the extensive clinical care network of AIC to expand the understanding of different SCIG products and maximize patient quality of life. This joint study between AIC and Grifols aims to bring valuable insights to the care of patients living with primary immune deficiencies.
I have over 10 years of experience in the cryptocurrency industry and I have been on the list of the top authors on LinkedIn for the past 5 years. I have a wealth of knowledge to share with my readers, and my goal is to help them navigate the ever-changing world of cryptocurrencies.
